The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 26, 2019

Filed:

Nov. 10, 2014
Applicant:

Abbvie Inc., North Chicago, IL (US);

Inventors:

Nathaniel Catron, Vernon Hills, IL (US);

David Lindley, Antioch, IL (US);

Jonathan M. Miller, Lindenhurst, IL (US);

Eric A. Schmitt, Libertyville, IL (US);

Ping Tong, Libertyville, IL (US);

Assignee:

AbbVie Inc., North Chicago, IL (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/397 (2006.01); A61K 31/5377 (2006.01); A61K 9/14 (2006.01); A61K 9/16 (2006.01); A61K 9/48 (2006.01); A61K 31/437 (2006.01); A61K 31/496 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5377 (2013.01); A61K 9/145 (2013.01); A61K 9/146 (2013.01); A61K 9/1617 (2013.01); A61K 9/1635 (2013.01); A61K 9/4866 (2013.01); A61K 31/437 (2013.01); A61K 31/496 (2013.01); Y02A 50/411 (2018.01);
Abstract

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.


Find Patent Forward Citations

Loading…